Endometrial cancer is a common gynaecological malignancy in the industrialised world. Unopposed stimulation of the endometrium by oestrogens is the classic aetiological factor associated with the development of this malignancy. However, not all are associated with oestrogen exposure and two different clinicopathological types can be distinguished: the oestrogen-related of endometrioid type (type I) and the non-oestrogen-related of non-endometrioid type (mainly papillary serous or clear cell carcinomas) (type II). Recent advances in the knowledge on the molecular genetics of endometrial cancer have shown that the molecular changes involved in its the development differ in oestrogen-dependent type I and non-oestrogen-dependent type II. Type I carcinomas frequently show mutations of DNA-mismatch repair genes (MLH1, MSH2, MSH6), PTEN, k-ras and beta-catenin genes whereas type II malignancies are characterised by aneuploidy, p53 mutations and her2/neu amplification. This article reviews the latest findings concerning common gene mutations involved in the development and progression of endometrial cancer.
. American Cancer Society. Cancer Facts and Figures, 2002. American Cancer Society, Atlanta, USA.
2.
. BokhmanJV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol1983; 15: 10–17.
3.
. ShermanMEBurMEKurmanRJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol1995; 26: 1268–1274.
4.
. LaxSFKendallBTashiroH. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer2000; 88: 814–824.
5.
. KolodnerR.Biochemstry and genetics of eukaryotic mismatch repair. Genes Dev1996; 10: 1433–1442.
6.
. JaninN.A simple model for carcinogenesis of colorectal cancers with microsatellite instability. Adv Cancer Res2000; 77: 189–221.
7.
. PeltomakiPVasenH.Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a colloborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology1997; 113: 1146–1158.
8.
. AarnioMSankilaRPukkalaE. Cancer risk in mutation carriers of DNA mismatch repair genes. Int J Cancer1999; 81: 214–218.
9.
. DunlopMGFarringtonSMCarothersAD. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet1997; 6: 105–110.
10.
. SharmaAJamesMDonaldsonAFoxR.Hereditary nonpolyposis colorectal cancer syndrome: combined risk of gastrointestinal and gynaecological cancer. Br J Cancer2001; 108: 671–677.
11.
. FornasarigMCampagnuttaETalaminiR. Risk factors for endometrial cancer according to familial susceptibility. Int J Cancer1998; 77: 29–33.
12.
. TashiroHLaxSFGaudinPB. Microsatellite instability is uncommon in uterine serous carcinoma. Am J Pathol1997; 150: 75–79.
13.
. EstellerMLevineRBaylinSB. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene1998; 17: 2413–2417.
14.
. InoueM.Current molecular aspects of the carcinogenesis of the uterine endometrium. Int J Gynecol Cancer2001; 11: 339–348.
15.
. BoguskiMSMcCormickF.Proteins regulation RAS and its relatives. Nature1993; 366: 643–654.
16.
. AdjeiAA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst2001; 93: 1062–74.
17.
. DugganBDFelixJCMuderspachLI. Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma. Cancer Res1994; 54: 1604–7.
18.
. LagardaHCatasusLArguellesR. K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol2001; 193: 193–9.
19.
. EstellerMXercavinsJReventosJ.Advances in the molecular genetics of endometrial cancer. Oncol Rep1999; 6: 1377–1382.
20.
. FujimotoIShimizuYHiraiY. Studies on ras oncogene activation in endometrial carcinoma. Gynecol Oncol1993; 48: 196–202.
21.
. EstellerMGarciaAMartinez-PalonesJM. The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer. Eur J Cancer1997; 33: 1572–1577.
22.
. SemczukABerbecHKostuchM. K-ras gene point mutations in human endometrial carcinomas: correlation with clinicopathological features and patients' outcome. J Cancer Res Clin Oncol1998; 124: 695–700.
23.
. ItoKWatanabeKNasimS. T. K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient. Gynecol Oncol1996; 63: 238–246.
24.
. SasakiHNishiiHTakahashiH. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res1993; 53: 1906–1910.
25.
. DugganBDFelixJCMuderspachLI. Microsatellite instability in sporadic endometrial carcinoma. J Natl Cancer Inst1994; 86: 1216–1221.
26.
. Graus-PortaDBeerliRRDalyJMHynesNE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalling. Embo J1997; 16: 1647–1655.
27.
. SpandidosDADokianakisDNKallergiGAggelakisE.Molecular basis of gynecological cancer. Ann N Y Acad Sci2000; 900: 56–64.
28.
. SaffariBJonesLAel-NaggarA. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res1995; 55: 5693–5698.
29.
. IoffeOBPapadimitriouJCDrachenbergCB. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol1998; 29: 1150–1159.
30.
. SantinADBelloneSGokdenM. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res2002; 8: 1271–1279.
31.
. RastyGMurrayRLuL. Expression of HER-2/neu oncogene in normal, hyperplastic, and malignant endometrium. Ann Clin Lab Sci1998; 28: 138–43.
32.
. BerchuckARodriguezGKinneyRB. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol1991; 164: 15–21.
33.
. RolitskyCDTheilKSMcGaughyVR. H. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol1999; 18: 138–143.
34.
. LukesASKohlerMFPieperCF. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer1994; 73: 2380–2385.
35.
. LattaEChapmanWB. PTEN mutations and evolving concepts in endometrial neoplasia. Curr Opin Obstet Gynecol2002; 14: 59–65.
36.
. CampbellRABhat-NakshatriPPatelNM. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem2001; 276: 9817–9824.
37.
. MarshDJCoulonVLunettaKL. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet1998; 7: 507–515.
38.
. Matias-GuiuXCatasusLBussagliaE. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol2001; 32: 569–577.
39.
. TashiroHBlazesMSWuR. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res1997; 57: 3935–3940.
40.
. RisingerJIHayesAKBerchuckABarrettJC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res1997; 57: 4736–4738.
41.
. KoulAWillenRBendahlPO. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer2002; 94: 2369–2379.
42.
. MutterGLLinMCFitzgeraldJT. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst2000; 92: 924–930.
43.
. LevineRLCargileCBBlazesMS. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res1998; 58: 3254–3258.
44.
. MutterGLInceTABaakJP. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res2001; 61: 4311–4314.
45.
. VousdenKHLuX.Live or let die: the cell's response to p53. Nat Rev Cancer2002; 2: 594–604.
46.
. BaergenRNWarrenCDIsacsonCEllensonLH. Early uterine serous carcinoma: clonal origin of extrauterine disease. Int J Gynecol Pathol2001; 20: 214–219.
47.
. CherchiPLMarrasVCapobiancoG. Prognostic value of p53, c-erb-B2 and MIB-1 in endometrial carcinoma. Eur J Gynaecol Oncol2001; 22: 451–453.
. MorinPJ. Beta-catenin signaling and cancer. Bioessays1999; 21: 1021–30.
50.
. LartigauEVituLHaie-MederC. Feasibility of measuring oxygen tension in uterine cervix carcinoma. Eur J Cancer1992; 28A(8–9): 1354–1357.
51.
. FukuchiTSakamotoMTsudaH. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res1998; 58: 3526–3528.
52.
. Mirabelli-PrimdahlLGryfeR. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res1999; 59: 3346–3351.
53.
. SaegusaMHashimuraMYoshidaTOkayasuI.Beta- catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer2001; 84: 209–217.
54.
. OehlerMKReesMCBicknellR.Steroids and the endometrium. Curr Med Chem2000; 7: 543–560.
55.
. CouseJFCurtis HewittSKorachKS. Receptor null mice reveal contrasting roles for estrogen receptor alpha and beta in reproductive tissues. J Steroid Biochem Mol Biol2000; 74: 287–296.
56.
. JazaeriOShupnikMAJazaeriAARiceLW. Expression of estrogen receptor alpha mRNA and protein variants in human endometrial carcinoma. Gynecol Oncol1999; 74: 38–47.
57.
. HorvathGLeserGHahlinMHenrikssonM.Exon deletions and variants of human estrogen receptor mRNA in endometrial hyperplasia and adenocarcinoma. Int J Gynecol Cancer2000; 10: 128–136.
58.
. LemieuxPFuquaS.The role of the estrogen receptor in tumor progression. J Steroid Biochem Molec Biol1996; 56: 87–91.
59.
. OehlerMK. Mechanism of action of steroid hormone receptors in the endometrium. J Br Meno Soc1999; 5: 103–108.
60.
. De VivoIHugginsGSHankinsonSE. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci USA2002; 99: 12263–12268.
